Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Company operates in three business segments. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications, vitamin drops and vaccines, among others. The Healthcare segment manufactures and sells general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of reagents, clinical diagnostics and chemical products. On September 30, 2011, the Company acquired 100% interests in Nycomed A/S. In January 2012, the Company acquired an America-based company.
|Headquarters||Takeda Midosuji Bldg.|
4-1-1, Dosho-machi, Chuo-ku
OSAKA-SHI, OSK, Japan 540-8645
|President, Representative Director||Yasuchika Hasegawa|
|President of Subsidiary, Director||Deborah Dunsire|
|Chief Commercial Officer, President of Subsidiary, Director||Frank Morich|
|Chief Medical and Scientific Officer, Director||Tadataka Yamada|
|Managing Director||Yasuhiko Yamanaka|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||--||Book Value||--|
|Annual Dividend Rate||$0.99||Price/Sales (TTM)||--|
|Ex-Div Date||9/25/12||P/Cash Flow (TTM)||--|
|Pay Date||12/13/12||Operating Margin||--|
*GAAP = prior to non-GAAP analyst adjusted earnings.